Search

Displaying results 3931 - 3940 of 8974 in total
  1. Drug

    Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10801
    ApprovedInvestigational

    Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … The vaccine contains *N. meningitis* serogroup W-135 capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from *Corynebacterium

  2. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases. … [A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time.

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  3. Drug

    Triheptanoin

    go.drugbank.com/drugs/DB11677
    ApprovedInvestigational

    [A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin. … [L14612] In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly

  4. Drug

    Cannabidivarin

    go.drugbank.com/drugs/DB14050
    Investigational

    In October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome [L2952] and again in February 2018 for treatment of Fragile X Syndrome [L2951]. … Compared to its homolog, [DB09061], CBDV is shortened by two methyl (CH2) groups on its side chain.

  5. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388]. … The drug made it to phase III trials before abandoned due to increased stroke.

  6. Drug

    Flecainide

    go.drugbank.com/drugs/DB01195
    ApprovedInvestigationalWithdrawn

    [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. … [A186931] It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.

  7. Drug

    Drostanolone propionate

    go.drugbank.com/drugs/DB14655
    ApprovedIllicit

  8. Drug

    Dimetindene

    go.drugbank.com/drugs/DB08801
    ApprovedInvestigational

    Dimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.

    Categories: Antihistamines for Topical Use, Antihistamines for Systemic Use
  9. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  10. Drug

    Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB21765
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes